Exicure Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jungsoo Kim

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

CEO

Jungsoo Kim (53 yo)

less than a year

Tenure

Mr. Jungsoo Kim is CEO and President at Exicure, Inc since February 11, 2026 and is its Director since February 09, 2026. He serves as Chairman & CEO of AGEDB Technology Ltd. since May 27,2025.He holds a...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jungsoo Kim	CEO, President & Director	less than a year	geen gegevens	geen gegevens
Gyuyeob Lee	Interim CFO & Secretary	less than a year	geen gegevens	geen gegevens
Young Ko	Chief Operating Officer	less than a year	geen gegevens	geen gegevens
Joshua Miller	Chief Accounting Officer	3.2yrs	geen gegevens	0.0047% € 409.5
Devki Sukhtankar	Head of Preclinical Research & Translational Medicine	less than a year	geen gegevens	geen gegevens
Niña Caculitan	Head of Clinical	less than a year	geen gegevens	geen gegevens

0.6yrs

Gemiddelde duur

49.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2H0 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.6 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jungsoo Kim	CEO, President & Director	less than a year	geen gegevens	geen gegevens
Dongho Lee	Independent Director	2.9yrs	US$20.00k	geen gegevens
Gyeung Cheon	Independent Director	less than a year	geen gegevens	geen gegevens
Yoontae Han	Director	less than a year	geen gegevens	geen gegevens
Eui Han	Independent Director	less than a year	geen gegevens	geen gegevens
Jin Go	Director	less than a year	geen gegevens	geen gegevens

0.3yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2H0 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.3 jaar), wat duidt op een nieuw bestuur.

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/07/31 18:13
Aandelenkoers aan het einde van de dag	2026/07/31 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Exicure, Inc. wordt gevolgd door 5 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
null null	BMO Capital Markets Equity Research
Keay Nakae	Chardan Capital Markets, LLC
Yatin Suneja	Guggenheim Securities, LLC

Exicure Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Exicure, Inc. Announces Board and Committee Changes, Effective June 30, 2026

Exicure, Inc. Announces Resignation of Director Sangjin Yeo from Board and Audit Committee, Effective March 27, 2026

Exicure, Inc. Announces Resignation of Andy Yoo as Chief Executive Officer, Effective February 9, 2026

Exicure, Inc. Announces New Leadership Strengthen Scientific and Clinical Capabilitie

Exicure, Inc., Annual General Meeting, Nov 06, 2025

Exicure, Inc. Announces Board Changes

Recent updates

Exicure, Inc. Announces Board and Committee Changes, Effective June 30, 2026

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. Announces Resignation of Director Sangjin Yeo from Board and Audit Committee, Effective March 27, 2026

Exicure, Inc. Announces Resignation of Andy Yoo as Chief Executive Officer, Effective February 9, 2026

Exicure, Inc. Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Exicure, Inc. Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma At 2025 Ash Annual Meeting

Exicure, Inc. Announces New Leadership Strengthen Scientific and Clinical Capabilitie

Exicure, Inc., Annual General Meeting, Nov 06, 2025

Exicure, Inc. Announces Board Changes

Exicure, Inc. Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. Receives Nasdaq Delinquency Notice on Late Filing of Its Form 10-Q

Exicure, Inc. announced delayed 10-Q filing

Exicure Completes Patient Enrollment in Phase 2 Study of Gpc-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. Announces Their Next Step in Planning for A New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure, Inc. Announces Board Resignations

Exicure, Inc. Announces Board Changes

Exicure Request for Subsequent Extension to Nasdaq Hearings Panel Till December 17

Nasdaq Hearings Panel Grants Exicure Extension for Continued Listing on The Nasdaq Capital Market, Compliance Required by November 14, 2024

Exicure Regains Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Exicure Announces 1-for-5 Reverse Stock Split to Regain Compliance with Nasdaq’s Listing Rules

High number of new and inexperienced directors

Exicure, Inc. Appoints Anna Chukaeva as Senior Vice President, Head of Corporate Development and Bioinformatics

Exicure Receives Positive Listing Determination from Nasdaq

Exicure Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(b)(1)

Exicure, Inc., Annual General Meeting, Jun 28, 2024

Exicure, Inc. Receives Nasdaq Notice of A Delisting Determination

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. announced delayed annual 10-K filing

New minor risk - Financial data availability

No independent directors

Exicure Receives Non-Compliance Notice From Nasdaq

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. Appoints Minhee Eom to the Board

Exicure Receives Non-Compliance Notice From Nasdaq

Exicure, Inc. Announces Executive Changes

Less than half of directors are independent

Exicure Notifies Nasdaq Regarding Continued to be Not in Compliance with Rule 5605(c)(2)(A)

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

CBI USA Inc Sends a Letter to Exicure Inc

Exicure, Inc. announced delayed 10-Q filing

No independent directors

Exicure, Inc. Announces Resignation of Jeffrey L. Cleland from the Board of Directors, Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

Exicure Receives Notice from Nasdaq Regarding No Longer in Compliance with Nasdaq's Independent Director and Audit Committee Requirements

Exicure, Inc. Announces Resignation of Jiyoung Hwang from the Board of Directors

Exicure, Inc. Announces Executive Changes

Exicure, Inc. Contemplates Bankruptcy

Exicure, Inc. announced that it expects to receive $5.44 million in funding from CBI Inc.

Exicure Receives Noncompliance Notice from Nasdaq

Second quarter 2022 earnings released

Exicure Regains Compliance with Nasdaq Minimum Bid Price Requirement

Exicure Announces Receipt of Nasdaq Notice of Non-Compliance

First quarter 2022 earnings released: US$0.069 loss per share (vs US$0.14 loss in 1Q 2021)

Exicure, Inc. announced that it expects to receive $5.040289 million in funding from CBI USA, Inc, Abingworth LLP

High number of new and inexperienced directors

Exicure, Inc., Annual General Meeting, May 27, 2022

Exicure, Inc. Announces Executive, Board and Committee Changes

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Exicure, Inc. Investors

Exicure Receives A Letter from the Staff Nasdaq Stock Market

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Exicure, Inc

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.049 loss in 2Q 2020)

Exicure, Inc.(NasdaqCM:XCUR) dropped from Russell Microcap Value Index

Exicure, Inc. Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients with Unmet Medical Needs

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2020)

Co-Founder & Director Chad Mirkin has left the company

Exicure, Inc. Announces Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients with Glioblastoma

Full year 2020 earnings released: US$0.28 loss per share (vs US$0.46 loss in FY 2019)

Revenue misses expectations

Exicure, Inc. Announces David R. Walt Did Not Stand for Re Election